Strategies for primary and secondary stroke prevention

Clinical Cardiology

Volumn 29, Issue 10 SUPPL., 2006, Pages

  Brass, Lawrence M ^a   Cuffe, Michael ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

Pharmacologic therapy; Primary prevention; Secondary prevention; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LISINOPRIL; LOSARTAN; NITRENDIPINE; PERINDOPRIL; RAMIPRIL;

ARTICLE; BLOOD PRESSURE MONITORING; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COST; DISABILITY; FINANCIAL MANAGEMENT; HIGH RISK PATIENT; HUMAN; INCIDENCE; LIFE EXPECTANCY; PRIMARY STROKE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; RISK REDUCTION; SECONDARY STROKE; STROKE;

ANTIHYPERTENSIVE AGENTS; CEREBROVASCULAR ACCIDENT; HUMANS; LOSARTAN; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; STROKE; TICLOPIDINE;

EID: 33749639512     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. American Heart Association: Heart Disease and Stroke-Statistical Update 2004. Dallas, Texas: American Heart Association, 1-52, 2004
2. World Health Organization: The WHO stroke surveillance system. World Health Organization 2004;August 23
3. Bonita R: Epidemiology of stroke. Lancet 1992;339(8789):342-344
4. Kokmen E, Whisnant JP, O'Fallon WM, Chu CP, Beard CM: Dementia after ischemic stroke: A population-based study in Rochester, Minnesota (1960-1984). Neurology 1996;46(1):154-159
5. Tatemichi TK, Paik M, Bagiella E, Desmond DW, Stern Y, Sano M, Hauser WA, Mayeux R: Risk of dementia after stroke in a hospitalized cohort: Results of a longitudinal study. Neurology 1994;44 (10):1885-1891
6. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB: Probability of stroke: A risk profile from the Framingham Study. Stroke 1991;22 (3):312-318
7. Sacco RL: Ischemic stroke. In Handbook of Neuroepidemiology (Eds. Gorelick PB, Alter MA), pp. 77-119. New York, N.Y.: Marcel Dekker, 1994
8. Wolf PA: Epidemiology of stroke. In Stroke: Pathophysiology, Diagnosis, and Management, 2nd ed. (Ed. Barnett HJM), pp. 3-27. Philadelphia: Churchill Livingstone, 1992
9. Kiely DK, Wolf PA, Cupples LA, Beiser AS, Myers RH: Familial aggregation of stroke. The Framingham Study. Stroke 1993;24(9):1366-1371
10. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350(9080):757-764
11. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358(9287):1033-1041
12. PROGRESS Collaborative Group: Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003;163(9):1069-1075
13. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, Davies R, Ostergren J, Probstfield J: Use of ramipril in preventing stroke: Double blind randomised trial. Br Med J 2002;324(7339):699-702
14. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359(9311):995-1003
15. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc 2002;288(23):2981-2997
16. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005;366(9489):895-906
17. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002;324(7329):71-86
18. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study 2: Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143(1-2):1-13
19. CAPRIE Steering Committee: A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348 (9038):1329-1339
20. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht H: Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischaemic Attack or Ischaemic Stroke (MATCH): Study design and baseline data. Cerebrovasc Dis 2004;17(2-3):253-261
21. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ: Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 suppl):429S-456S
22. Halperin JL: Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003;146(3):431-438
23. Olsson SB: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomised controlled trial. Lancet 2003;362(9397):1691-1698
24. Wannamethee SG, Shaper AG, Ebrahim S: HDL-cholesterol, total cholesterol, and the risk of stroke in middle-aged British men. Stroke 2000;31(8):1882-1888
25. Shahar E, Chambless LE, Rosamond WD, Boland LL, Ballantyne CM, McGovern PG, Sharrett AR: Plasma lipid profile and incident ischemic stroke: The Atherosclerosis Risk in Communities (ARIC) study. Stroke 2003;34(3):623-631
26. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD: Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989;320(14):904-910
27. Benfante R, Hwang LJ, Masaki K, Curb JD: To what extent do cardiovascular risk factor values measured in elderly men represent their midlife values measured 25 years earlier? A preliminary report and commentary from the Honolulu Heart Program. Am J Epidemiol 1994;140(3):206-216
28. Horenstein RB, Smith DE, Mosca L: Cholesterol predicts stroke mortality in the Women's Pooling Project. Stroke 2002;33(7):1863-1868
29. Byington RP, Davis BR, Plehn JF, White HD, Baker J, Cobbe SM, Shepherd J: Reduction of stroke events with pravastatin: The Prospective Pravastatin Pooling (PPP) Project. Circulation 2001;103 (3):387-392
30. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333(20):1301-1307
31. Sacks FM, Pfeffer MA, Moyé LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335(14):1001-1009
32. LIPID Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. N Engl J Med 1998;339(19):1349-1357
33. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Österfren J: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003;361(9364):1149-1158
34. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360(9326):7-22
35. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH: Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001;87(7):819-822
36. Ovbiagele B, Saver JL, Fredieu A, Suzuki S, McNair N, Dandekar A, Razinia T, Kidwell CS: PROTECT: A coordinated stroke treatment program to prevent recurrent thromboembolic events. Neurology 2004;63(7):1217-1222
37. Ovbiagele B, Saver JL, Fredieu A, Suzuki S, Selco S, Rajajee V, McNair N, Razinia T, Kidwell CS: In-hospital initiation of secondary stroke prevention therapies yields high rates of adherence at follow-up. Stroke 2004;35(12):2879-2883